Using Abemaciclib to Treat Traumatic Brain Injury

Abstract

Researchers at the University of California, Davis have developed a technology that provides a method for treating traumatic brain injury (TBI) using a therapeutically effective dose of a selective cyclin-dependent kinase 4 (CDK4)/cyclin-dependent kinase 6 (CDK6) inhibitor.

Full Description

The technology introduces a method comprising of administering a selective CDK4/CDK6 inhibitor for the treatment of TBI. This treatment can be effected during the acute stage of TBI, within about 0.1 to 9 hours following the incident, and depending on the severity of the injury, the administration of the inhibitor might be oral or intravenous. The approach is designed to reduce secondary brain injury, preserve neuronal function, and improve recovery following TBI.

Applications

• Treatment of TBI in emergency medical settings. 
• Use in chronic management of TBI effects. 
• Potential use in other neuronal disorders treatment.

Features/Benefits

• Provides treatment for TBI, where there's currently no FDA-approved drug. 
• Promotes hippocampal neuronal survival following TBI. 
• Improves cognitive and motor function in patients. 
• Decreases symptoms of TBI-induced brain damage. 
• Decreases side effects compared to higher doses of the inhibitor. 
• Addresses lack of approved treatment for TBI. 
• Addresses decrease in motor and cognitive dysfunctions related to TBI. 
• Minimizes side-effects of high-dose treatments.

Patent Status